BridgeBio Pharma, Inc. (BBIO) Wednesday announced FDA clearance for its investigational new drug application for BBO-8520, an orally bioavailable, small molecule direct inhibitor of KRASG12C (ON) state in patients with KRASG12C mutant cancers.
BBO-8520 binds covalently to the Switch II pocket in both the GTP-bound (ON) and GDP-bound (OFF) state conformations of KRASG12C, leading to rapid and robust inhibition of KRASG12C activity.
The commercial-stage biopharmaceutical company focused on genetic diseases and cancers said BBO-8520 could drive substantial tumor growth inhibition in multiple preclinical models.
Enrollment of patients with KRASG12C mutant non-small cell lung cancer into the ONKORAS-101 trial is expected to begin in H1 of this year.
For comments and feedback contact: editorial@rttnews.com
Business News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.